ATE429216T1 - Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson - Google Patents

Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson

Info

Publication number
ATE429216T1
ATE429216T1 AT03774642T AT03774642T ATE429216T1 AT E429216 T1 ATE429216 T1 AT E429216T1 AT 03774642 T AT03774642 T AT 03774642T AT 03774642 T AT03774642 T AT 03774642T AT E429216 T1 ATE429216 T1 AT E429216T1
Authority
AT
Austria
Prior art keywords
disease
alpha
parkinson
alzheimer
treatment
Prior art date
Application number
AT03774642T
Other languages
English (en)
Inventor
Larry Wheeler
Daniel Gil
John Donello
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE429216T1 publication Critical patent/ATE429216T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03774642T 2002-10-08 2003-10-07 Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson ATE429216T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41704902P 2002-10-08 2002-10-08
PCT/US2003/031809 WO2004032913A1 (en) 2002-10-08 2003-10-07 Alpha 2b 0r 2b/2c adrenoceptor agonists for the treatment of neurodegeneration

Publications (1)

Publication Number Publication Date
ATE429216T1 true ATE429216T1 (de) 2009-05-15

Family

ID=32093954

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03774642T ATE429216T1 (de) 2002-10-08 2003-10-07 Alpha 2b oder 2b/2c adrenozeptor-agonisten zur behandlung von morbus alzheimer und morbus parkinson

Country Status (20)

Country Link
US (1) US20040138312A1 (de)
EP (1) EP1549305B1 (de)
JP (2) JP4724421B2 (de)
KR (1) KR20050050124A (de)
CN (1) CN100431536C (de)
AT (1) ATE429216T1 (de)
AU (2) AU2003282758A1 (de)
BR (1) BR0314540A (de)
CA (1) CA2501347A1 (de)
DE (1) DE60327335D1 (de)
ES (1) ES2322954T3 (de)
HK (1) HK1081880A1 (de)
IL (1) IL167849A (de)
MX (1) MXPA05003664A (de)
NO (1) NO20051663L (de)
NZ (1) NZ539328A (de)
PL (1) PL216373B1 (de)
RU (1) RU2330649C2 (de)
WO (1) WO2004032913A1 (de)
ZA (1) ZA200502744B (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2007206A4 (de) * 2006-03-16 2010-12-08 Yeda Res & Dev Verfahren und zusammensetzung für den schutz von nervengewebe gegen schädigung durch hohe glutaminkonzentrationen
WO2009052075A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating motor disorders with alpha-2b adrenergic receptor agonists
US20100216857A1 (en) * 2007-10-18 2010-08-26 Luhrs Lauren M B Method of treating motor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione
WO2009052073A2 (en) * 2007-10-18 2009-04-23 Allergan, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists
JP5705742B2 (ja) * 2008-12-08 2015-04-22 アラーガン インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ アルファ２ｂまたはアルファ２ｂおよびアルファ２ｃアドレノセプターのサブタイプ選択性モジュレーターとしてのｎ‐（１‐フェニル‐２‐アリールエチル）‐４，５‐ジヒドロ‐３ｈ‐ピロール‐２‐アミン化合物
EP4371554A2 (de) 2016-12-31 2024-05-22 BioXcel Therapeutics, Inc. Verwendung von sublingualem dexmedetomidin zur behandlung von unruhe
CN114983980A (zh) 2018-06-27 2022-09-02 比奥克斯塞尔医疗股份有限公司 含右美托咪定的膜制剂及其制造方法
BR112022000992A2 (pt) 2019-07-19 2022-06-14 Arx Llc Regimes de tratamento de dexmedetomidina não sedantes
US11806334B1 (en) 2023-01-12 2023-11-07 Bioxcel Therapeutics, Inc. Non-sedating dexmedetomidine treatment regimens

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4029792A (en) * 1972-02-29 1977-06-14 Pfizer Inc. (2-Imidazolin-2-ylamino) substituted -quinoxalines and -quinazolines as antihypertensive agents
BE795970A (fr) * 1972-02-29 1973-08-27 Pfizer Nouveaux derives de quinoleine, quinoxaline et quinazoline er composition pharmaceutiques les contenant
US5210076A (en) * 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
US6194415B1 (en) * 1995-06-28 2001-02-27 Allergan Sales, Inc. Method of using (2-imidazolin-2-ylamino) quinoxoalines in treating neural injury
US6329369B1 (en) * 1997-12-04 2001-12-11 Allergan Sales, Inc. Methods of treating pain and other conditions
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
EP1413576A3 (de) * 1997-12-04 2004-09-01 Allergan, Inc. Substituierte Imidazolderivate und deren Verwendung als Agonisten der alpha 2B oder 2B/2C adrenergischen Rezeptoren
US6313172B1 (en) * 2000-04-13 2001-11-06 Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity
IL151530A0 (en) * 2000-07-14 2003-04-10 Allergan Sales Inc Compositions containing alpha-2-adrenergic agonist components
AU2002248284A1 (en) * 2000-11-01 2002-08-06 Allergan, Inc. Compositions for treatment of ocular neovascularization
US7091232B2 (en) * 2002-05-21 2006-08-15 Allergan, Inc. 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl) imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds

Also Published As

Publication number Publication date
US20040138312A1 (en) 2004-07-15
BR0314540A (pt) 2005-07-26
HK1081880A1 (en) 2006-05-26
JP2006504739A (ja) 2006-02-09
DE60327335D1 (de) 2009-06-04
CA2501347A1 (en) 2004-04-22
CN100431536C (zh) 2008-11-12
PL376346A1 (en) 2005-12-27
JP4724421B2 (ja) 2011-07-13
AU2009238370B2 (en) 2011-07-21
MXPA05003664A (es) 2005-06-08
PL216373B1 (pl) 2014-03-31
NZ539328A (en) 2007-01-26
AU2003282758A1 (en) 2004-05-04
AU2009238370A1 (en) 2009-12-17
IL167849A (en) 2011-04-28
CN1703213A (zh) 2005-11-30
EP1549305B1 (de) 2009-04-22
WO2004032913A1 (en) 2004-04-22
ES2322954T3 (es) 2009-07-02
NO20051663L (no) 2005-05-31
RU2005114504A (ru) 2005-10-27
ZA200502744B (en) 2006-02-22
JP2011057700A (ja) 2011-03-24
RU2330649C2 (ru) 2008-08-10
EP1549305A1 (de) 2005-07-06
KR20050050124A (ko) 2005-05-27

Similar Documents

Publication Publication Date Title
NO20050807L (no) Farmasoytiske sammensetninger som innbefatter dekstrometorfan og kinidin for behandling av neurologiske forstyrrelser
ATE480255T1 (de) Zusammensetzungen und verfahren zur kontrolle, prävention und behandlung von essstörungen
WO2004026246A3 (en) Methods of treating age associated memory impairment (aami), mild cognitive impairment (mci), and dementias with cell cycle inhibitors
GB0223038D0 (en) Therapeutic compounds
HK1081880A1 (en) Alpha 2b or 2b/2c adrenoceptor agonists for the treatment of neurodegeneration
GB0225474D0 (en) Therapeutic agents
CY1115617T1 (el) Χρηση της εποθιλονης κατα τη θεραπευτικη αγωγη νοσηματων τα οποια σχετιζονται με την πρωτεϊνη ταu εις τα οποια συμπεριλαμβανεται η νοσος του αlzheimer
ATE409176T1 (de) 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen
ATE423990T1 (de) Verfahren und zusammensetzungen zur behandlung von uveitis
ATE369861T1 (de) Pteridin-derivate zur behandlung von erkrankungen im zusammenhang mit tnf-alpha
DE60228073D1 (de) Adenosin-a1-rezeptorantagonisten zur behandlung von hypoxiebedingten lern- und gedächtnisstörungen
DE60312736D1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
ATE355054T1 (de) Verfahren und verbindungen zur behandlung der depression
CY1109666T1 (el) Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας
NO20051664L (no) Behandling av demens og Parkinsons sykdom
MX2020009532A (es) Oligonucleotidos modificados para uso en el tratamiento de tauopatias.
NO20044530L (no) Fremgangsmate for behandling av kognitive forstyrrelser
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
ATE425967T1 (de) Piperazin und piperadin-derivate fur die behandlung von neurologischen krankheiten
NO20054034L (no) Fremgangsmate for behandling av hypotyroidisme.
MXPA05004121A (es) Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
ATE482217T1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
ATE428436T1 (de) Mittel zur behandlung oder prävention allergischer erkrankungen mit bearbeitetem erdnusssamen-überzug

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties